Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2009

AstraZeneca to Help UCB Launch RA/Crohn’s Drug in Brazil

  • AstraZeneca has taken on Brazilian rights to UCB’s Cimzia®, approved in the U.S. for rheumatoid arthritis (RA) and Crohn’s disease. AstraZeneca may also distribute line extensions related to Cimzia in Brazil, while UCB retains the right to co-promote Cimzia and line extensions in the country.

    UCB is developing Cimzia in other autoimmune disease like lupus as well as fracture healing and post-menopausal osteoporosis. The drug is at the Phase II stage for all indications.

    AstraZeneca is responsible for registration and upon approval will be the exclusive distributor of Cimzia, an PEGylated anti-TNF alpha compound in Brazil. Initial registration activities will focus on RA and Crohn’s.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »